Opinion and Evidence in Respiratory Medicine
- PDF / 90,641 Bytes
- 4 Pages / 612 x 790.56 pts Page_size
- 12 Downloads / 185 Views
Am J Respir Med 2002; 1 (4): 301-304 1175-6365/02/0004-0301/$25.00/0 © Adis International Limited. All rights reserved.
Opinion and Evidence in Respiratory Medicine Contents Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1. Montelukast: Role in Adenosine 5’- Monophosphate-Induced Bronchoconstriction . . . . 2. Formoterol Cost Effective for Pediatric Asthma in the UK . . . . . . . . . . . . . . . . . . . . 3. Theophylline Shows Anti-Inflammatory Effects in Chronic Obstructive Pulmonary Disease 4. Asthma Treatment not Compliant with Guidelines in Italy . . . . . . . . . . . . . . . . . . . 5. Routine Zinc Supplementation Reduces Pneumonia . . . . . . . . . . . . . . . . . . . . . . 6. Fluticasone Propionate + Salmeterol Cost Saving Dual Therapy in Asthma . . . . . . . . . 7. Albuterol Delivered by Metered Dose Inhaler/Spacer Preferred in Acute Asthma . . . . . 8. Salmeterol Reduces Risk of High-Altitude Pulmonary Edema . . . . . . . . . . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
301 301 301 302 302 302 303 303 304
Respiratory Medicine is a vast and evolving area for researchers, primary care physicians and specialists. To help keep you up-to-date with the latest advances worldwide on all aspects of drug therapy and management of respiratory disorders, this section of the journal brings you information selected from the drug therapy reporting service Inpharma Weekly1. The following reports are selected from the latest issues, summarizing the most important research and development news, clinical studies, treatment guidelines, pharmacoeconomic and adverse reaction news, and expert opinion pieces published across a broad range of literature sources.
1. Montelukast: Role in Adenosine 5′- Monophosphate-Induced Bronchoconstriction Adenosine 5′-monophosphate (AMP)-induced bronchoconstriction is reduced by the cysteinyl leukotriene-1 receptor-selective antagonist, montelukast, in patients with mild-to-moderate persistent asthma, report researchers from the UK. Eighteen such patients received oral montelukast 10mg and placebo, once daily for two consecutive days, in a crossover fashion. A 14-day washout period separated each treatment phase. Bronchoconstriction was induced by using incremental doses of AMP 0.39 to 400 mg/ml inhaled by dosimeter at 5-minute intervals. The concentration of AMP required to decrease forced expiratory volume in 1 second (FEV1) by 20% from baseline was 51.6 mg/ml after placebo administration and 126.5 mg/ml after montelukast administration. In three patients, the maximum con-
centration of AMP failed to produce the 20% reduction in FEV1 after treatment with montelukast. The researchers interp
Data Loading...
